DROID: dose-ranging approach to optimizing dose in oncology drug development
From MaRDI portal
Publication:6589229
Cites work
- A Bayesian phase I/II trial design for immunotherapy
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- Bayesian designs for phase I--II clinical trials
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian inference on order-constrained parameters in generalized linear models
- Bayesian optimal interval designs for phase I clinical trials
- Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points
- scientific article; zbMATH DE number 193111 (Why is no real title available?)
Cited in
(7)- Design and sample size determination for multiple-dose randomized phase II trials for dose optimization
- A seamless phase II/III design with dose optimization for oncology drug development
- Randomized optimal selection design for dose optimization
- Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designs
- COMIC: a Bayesian dose optimization design for drug combination in multiple indications with application to CAR-T therapies
- UNITED: a unified transparent and efficient phase I/II trial design for dose optimization accounting for ordinal graded, continuous and mixed toxicity and efficacy endpoints
- ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications
This page was built for publication: DROID: dose-ranging approach to optimizing dose in oncology drug development
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6589229)
